Table 1.
Demographic details (mean ± sd). The sample comprised healthy controls (HC) and those with subjective cognitive decline (SCD)). All participants had an MMSE score ≥ 25 and did not exhibit clinically relevant amyloid deposition (i.e., PET negative). [18F] Flutemetamol SUVR, standard uptake value ratios of brain regions prone to early amyloid uptake (Fig. 1); MMSE, mini mental state examination score. Delayed recall, 10-word delayed recall part of the Alzheimer’s disease assessment scale (number of errors out of 10); AQT, a quick test of cognitive speed color-form version (reaction time in seconds); APOE ε4, carriers of 1 or 2 alleles; History, family history of dementia in first degree relatives
| HC | SCD | All | |
|---|---|---|---|
| n | 85 | 48 | 133 |
| Sex (m/f) | 32/53 | 20/28 | 52/81 |
| Age (years) | 73.7 ± 4.2 | 68.9 ± 5.5 | 72.0 ± 5.2 |
| [18F] Flutemetamol SUVR | 0.58 ± 0.06 | 0.61 ± 0.06 | 0.59 ± 0.06 |
| MMSE | 29.0 ± 1.0 | 28.9 ± 1.4 | 29.0 ± 1.2 |
| Delayed recall (errors) | 1.8 ± 1.9 | 2.7 ± 2.0 | 2.1 ± 2.0 |
| AQT (s) | 66.5 ± 12.6 | 72.3 ± 24.9 | 68.6 ± 18.1 |
| Education (years) | 11.8 ± 3.1 | 13.8 ± 3.1 | 12.5 ± 3.2 |
| APOE e4 (%) | 20.0 | 29.2 | 23.3 |
| History (%) | 30.6 | 47.9 | 36.8 |